RxDoctor Payments Data

Steven Hays, MD

Internal Medicine · San Francisco, CANPI 1174570576

Payments from drug & device makers

$87,395in general payments, 2019–2025

Across 47 payments — averaging $1859.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$72K
  • Zambon USA Ltd.$7K
  • Grifols Shared Services North America, Inc.$6K
  • Mallinckrodt Hospital Products Inc.$2K
  • Paragonix Technologies, Inc.$279
  • United Therapeutics Corporation$225
  • plus $296 from 7 others

What the payments were for

  • Consulting fees$6,82044%
  • Speaking & faculty fees$5,63536%
  • Travel & lodging$2,05913%
  • Food & beverage$9806%

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,395 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$48,952
Medicare patients
163
Services billed
580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor25$363,508
ZemairaAlpha-1-Proteinase Inhibitor14$140,865
GlassiaAlpha-1-Proteinase Inhibitor14$135,892
OfevNintedanib Esylate11$127,808
Aralast NpAlpha-1-Proteinase Inhibitor11$103,646
PrevymisLetermovir11$89,959
Valganciclovir Hcl106$38,048
Atovaquone18$14,939
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,971
EliquisApixaban12$8,008
Dapsone79$3,188
Tacrolimus27$2,499
Mycophenolate Mofetil25$2,051
Fluconazole91$1,628
Prednisone139$1,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Glassia$31$135,89214 claims
Boehringer IngelheimOfev$51$127,80811 claims
GSKTrelegy Ellipta$20$12,97111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →